Search

Home > Cell & Gene: The Podcast > Pivoting to Allogeneic CAR-T Therapies with Celyad Oncology’s CMO, Dr. Charlie Morris
Podcast: Cell & Gene: The Podcast
Episode:

Pivoting to Allogeneic CAR-T Therapies with Celyad Oncology’s CMO, Dr. Charlie Morris
Category: Science & Medicine
Duration: 00:25:21
Publish Date: 2022-04-14 08:00:00
Description:

Celyad Oncology’s CMO, Dr. Charlie Morris, shares the benefits and challenges of the allogeneic approach versus the autologous approach and why a non-gene edited shRNA approach may result in better efficacy and safety for CAR-T therapies.
Total Play: 0